562 related articles for article (PubMed ID: 22496518)
1. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
[TBL] [Abstract][Full Text] [Related]
2. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
3. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
Doshi LS; Brahma MK; Bahirat UA; Dixit AV; Nemmani KV
Expert Opin Investig Drugs; 2010 Apr; 19(4):489-512. PubMed ID: 20367191
[TBL] [Abstract][Full Text] [Related]
5. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
[TBL] [Abstract][Full Text] [Related]
6. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
7. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
[TBL] [Abstract][Full Text] [Related]
8. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
[TBL] [Abstract][Full Text] [Related]
9. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
11. Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.
Acton JJ; Akiyama TE; Chang CH; Colwell L; Debenham S; Doebber T; Einstein M; Liu K; McCann ME; Moller DE; Muise ES; Tan Y; Thompson JR; Wong KK; Wu M; Xu L; Meinke PT; Berger JP; Wood HB
J Med Chem; 2009 Jul; 52(13):3846-54. PubMed ID: 19507861
[TBL] [Abstract][Full Text] [Related]
12. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
[TBL] [Abstract][Full Text] [Related]
13. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
14. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
[TBL] [Abstract][Full Text] [Related]
15. Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands.
Rival Y; Stennevin A; Puech L; Rouquette A; Cathala C; Lestienne F; Dupont-Passelaigue E; Patoiseau JF; Wurch T; Junquéro D
J Pharmacol Exp Ther; 2004 Nov; 311(2):467-75. PubMed ID: 15273253
[TBL] [Abstract][Full Text] [Related]
16. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
17. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.
Muise ES; Azzolina B; Kuo DW; El-Sherbeini M; Tan Y; Yuan X; Mu J; Thompson JR; Berger JP; Wong KK
Mol Pharmacol; 2008 Aug; 74(2):403-12. PubMed ID: 18467542
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
[TBL] [Abstract][Full Text] [Related]
19. Regulation of selective PPARγ modulators in the differentiation of osteoclasts.
Wu H; Li L; Ma Y; Chen Y; Zhao J; Lu Y; Shen P
J Cell Biochem; 2013 Sep; 114(9):1969-77. PubMed ID: 23494891
[TBL] [Abstract][Full Text] [Related]
20. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
Berger JP; Petro AE; Macnaul KL; Kelly LJ; Zhang BB; Richards K; Elbrecht A; Johnson BA; Zhou G; Doebber TW; Biswas C; Parikh M; Sharma N; Tanen MR; Thompson GM; Ventre J; Adams AD; Mosley R; Surwit RS; Moller DE
Mol Endocrinol; 2003 Apr; 17(4):662-76. PubMed ID: 12554792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
